Integrating palliative care with chronic liver disease care

Journal of Palliative Care

Volumn 27, Issue 1, 2011, Pages 20-27

  Morrison, R S ^a   Hope, A A ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Pulmonary Division   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASCITES; CHRONIC DISEASE; HUMAN; INTEGRATED HEALTH CARE SYSTEM; LIVER DISEASE; NEEDS ASSESSMENT; ORGANIZATION AND MANAGEMENT; PALLIATIVE THERAPY; PATIENT CARE; PROGNOSIS; PRURITUS; QUALITY OF LIFE; REVIEW; VARICOSIS;

ADVANCE CARE PLANNING; ASCITES; CHRONIC DISEASE; DELIVERY OF HEALTH CARE, INTEGRATED; HUMANS; LIVER DISEASES; NEEDS ASSESSMENT; PALLIATIVE CARE; PROGNOSIS; PRURITUS; QUALITY OF LIFE; VARICOSE VEINS;

EID: 79959593417     PISSN: 08258597     EISSN: None     Source Type: Journal    
DOI: 10.1177/082585971102700105     Document Type: Review

References (94)

1. Zaklm D, Boyer TD, editors. Hepatology: a textbook of liver disease. Philadelphia: W.B. Saunders; 2003.
2. Fox E, Landrum-McNiff K, Zhong Z, et al. Evaluation of prognostic criteria for determining hospice eligibility in patients with advanced lung, heart, or liver disease. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Out-comes and Risks of Treatments. JAMA 1999; 282(17): 1638-1645.
3. Guy V. Liver failure, life support, family support, and palliation: an inside story. J Crit Care 2006; 21(3): 250-252. (Pubitemid 44380346)
4. Bajaj JS. Minimal hepatic encephalopathy matters in daily life. World J Gastroenterol 2008; 14(23): 3609-3615.
5. Schomerus H, Hamster W. Quality of life in cirrhotics with minimal hepatic encephalopathy. Metabolic Brain Disease 2001; 16(1-2): 37-41. (Pubitemid 33064035)
6. Sanchez W, Talwalkar JA. Palliative care for patients with endstage liver disease ineligible for liver transplantation. Gastroenterol Clin North Am 2006; 35(1): 201-219. (Pubitemid 43356597)
7. Larson AM, Curtis JR. Integrating palliative care for liver transplant candidates: "Too well for transplant, too sick for life." JAMA 2006; 295(18): 2168-2176.
8. Christakis NA. Death foretold: prophecy and prognosis in medical care. Chicago: University of Chicago Press; 1999.
9. Roth K, Lynn J, Zhong Z, et al. Dying with end stage liver disease with cirrhosis: insights from SUPPORT. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment. J Am Geriatr Soc 2000; 48(5 Suppl): S122-S130.
10. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44(1): 217-231. (Pubitemid 41772537)
11. Garcia-Tsao G, Lim JK. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol 2009; 104(7): 1802-1829.
12. Ginès P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7(1): 122-128. (Pubitemid 17019862)
13. Carbonell N, Pauwels A, Serfaty L, et al. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology 2004; 40(3): 652-659. (Pubitemid 39265587)
14. Planas R, Montoliu S, Ballesté B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clinical Gastroenterol Hepatol 2006; 4(11): 1385-1394.
15. Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49(6): 2087-2107.
16. Arroyo V, Terra C, Ginès P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J Hepatol 2007; 46(5): 935-946. (Pubitemid 46529046)
17. Alessandria C, Ozdogan O, Guevara M, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2005; 41(6): 1282-1289. (Pubitemid 40770280)
18. Child CG. Surgery and portal hypertension. In: Child CG, editor. The liver and portal hypertension. Philadelphia: W.B. Saunders; 1964.
19. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60(8): 646-649.
20. Fernández-Esparrach G, Sanchez-Fueyo A, Ginès P, et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001; 34(1): 46-52. (Pubitemid 32102551)
21. Planas R, Bailasté B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis: a study of 200 patients. J Hepatol 2004; 40(5): 823-830. (Pubitemid 38507364)
22. Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31(4): 864-871. (Pubitemid 30169932)
23. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001 ; 33(2): 464-470. (Pubitemid 32119037)
24. Chalasani N, Kahi C, Francois F, et al. Model for end-stage liver disease (MELD) for predicting mortality in patients with acute variceal bleeding. Hepatology 2002; 35(5): 1282-1284. (Pubitemid 34454029)
25. Antaki F, Lukowski A. The model for end-stage liver disease (MELD) predicts survival of liver cirrhosis patients after discharge to hospice. J Clin Gastroenterol 2007; 41(4): 412-415. (Pubitemid 46573072)
26. Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Advanced Liver Disease Study Group. Hepatology 2007; 45(3): 797-805. (Pubitemid 46450631)
27. Sanyal AJ, Bosch J, Blei A, et al. Portal hypertension and its complications. Gastroenterology 2008; 134(6): 1715-1728. (Pubitemid 351626956)
28. Ruf AE, Kremers WK, Chavez LL, et al. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005; 11(3): 336-343. (Pubitemid 40458408)
29. Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008; 359(10): 1018-1026.
30. Biggins SW, Rodriguez HJ, Bacchetti P, et al. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2005; 4(1): 32-39. (Pubitemid 40066380)
31. Londono M-C, Cárdenas A, Guevara M, et al. MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut 2007; 56(9): 1283-1290. (Pubitemid 47300431)
32. Schenk P, Schoniger-Hekele M, Fuhrmann V, et al. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology 2003; 125(4): 1042-1052. (Pubitemid 37193451)
33. Swanson KL, Wiesner RH, Krowka MJ. Natural history of hepatopulmonary syndrome: impact of liver transplantation. Hepatology 2005; 41 (5): 1122-1129. (Pubitemid 40593920)
34. Durand F, Valla D. Assessment of prognosis of cirrhosis. Semin Liver Dis 2008; 28(1): 110-122. (Pubitemid 351326537)
35. Wehler M, Kokoska J, Reulbach U, et al. Short-term prognosis in critically ill patients with cirrhosis assessed by prognostic scoring systems. Hepatology 2001; 34(2): 255-261. (Pubitemid 32702337)
36. Dhainaut J-F, Laterre P-F, Janes JM, et al. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med 2003; 29(6): 894-903. (Pubitemid 36783159)
37. Devulder J, Richarz U, Nataraja SH. Impact of long-term use of opioids on quality of life in patients with chronic, non-malignant pain. Curr Med Res Opin 2005; 21(10): 1555-1568.
38. Rhee C, Broadbent AM. Palliation and liver failure: palliative medications dosage guidelines. J Palliat Med 2007; 10(3): 677-685. (Pubitemid 47025667)
39. Murray MD, Brater DC. Renal toxicity of the nonsteroidal antiinflammatory drugs. Annu Rev Pharmacacol Toxicol 1993; 33: 435-465. (Pubitemid 23116014)
40. Giovanni G, Giovanni P. Do non-steroidal anti-inflammatory drugs and COX-2 selective inhibitors have different renal effects? J Nephrol 2002; 15(5): 480-488.
41. Prescott LF. Therapeutic misadventure with paracetamol: fact or fiction? Am J Ther 2000; 7(2): 99-114.
42. Benson GD, Koff RS, Tolman KG. The therapeutic use of acetaminophen in patients with liver disease. Am J Ther 2005; 12(2): 133-141. (Pubitemid 40516030)
43. Dart RC, Kuffner EK, Rumack BH. Treatment of pain or fever with paracetamol (acetaminophen) in the alcoholic patient: a systematic review. Am J Ther 2000; 7(2): 123-134.
44. Kuffner EK, Green JL, Bogdan GM, et al. The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients: a multicenter randomized study. BMC Med 2007; 5:13.
45. Tegeder I, Lötsch J, Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet 1999; 37(1): 17-40.
46. Novick DM, Kreek MJ, Fanizza AM, et al. Methadone disposition in patients with chronic liver disease. Clin Pharmacol Ther 1981; 30(3): 353-362. (Pubitemid 11061959)
47. Marchesini G, Bianchi G, Amodio P, et al. Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology 2001; 120(1): 170-178. (Pubitemid 32061881)
48. Lebovics E, Seif F, Kim D, et al. Pruritus in chronic hepatitis C: association with high serum bile acids, advanced pathology, and bile duct abnormalities. Dig Dis Sci 1997; 42(5): 1094-1099. (Pubitemid 27239807)
49. Kremer AE, Beuers U, Oude-Elferink RPJ, et al. Pathogenesis and treatment of pruritus in cholestasis. Drugs 2008; 68(15): 2163-2182.
50. Bergasa NV. Medical palliation of the jaundiced patient with pruritus. Gastroenterol Clin North Am 2006; 35(1): 113-123. (Pubitemid 43356591)
51. Mela M, Mancuso A, Burroughs AK. Review article: pruritus in cholestatic and other liver diseases. Aliment Pharmacol Ther 2003; 17(7): 857-870. (Pubitemid 36459598)
52. Marzioni M, Svegliati Baroni G, Alpini G, et al. Endogenous opioid peptides and chronic liver disease: from bedside to bench. J Hepatol 2007; 46(4): 583-586. (Pubitemid 46431168)
53. Tandon P, Rowe BH, Vandermeer B, et al. The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol 2007; 102(7): 1528-1536. (Pubitemid 46976283)
54. Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrhosis. BMJ 1988; 297(6662): 1501-1504. (Pubitemid 19007547)
55. Jones EA, Neuberger J, Bergasa NV. Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions. QJM 2002; 95(8): 547-552. (Pubitemid 34919145)
56. Bergasa NV, Schmitt JM, Talbot TL, et al. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 1998; 27(3): 679-684. (Pubitemid 28103542)
57. Carson KL, Tran TT, Cotton P, et al. Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease. Am J Gastroenterol 1996; 91(5): 1022-1023. (Pubitemid 26143548)
58. Dawn AG, Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol 2006; 54(3): 527-531. (Pubitemid 43245656)
59. Santos J, Planas R, Pardo A, et al. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis: a randomized comparative study of efficacy and safety. J Hepatol 2003; 39(2): 187-192. (Pubitemid 36920553)
60. Salerno F, Badalamenti S, lncerti P, et al. Repeated paracentesis and i.v. albumin infusion to treat "tense" ascites in cirrhotic patients: a safe alternative therapy. J Hepatol 1987; 5(1): 102-108.
61. Ginès P, Arroyo V, Quintero E, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites: results of a randomized study. Gastroenterology 1987; 93(2): 234-241. (Pubitemid 17097585)
62. Cárdenas A, Ginès P. Management of refractory ascites. Clin Gastroenterol Hepatol 2005; 3(12): 1187-1191. (Pubitemid 41797668)
63. Cárdenas A, Ginès P, Runyon BA. Is albumin infusion necessary after large volume paracentesis? Liver lnt 2009; 29(5): 636-640.
64. Runyon BA. Treatment of patients with cirrhosis and ascites. Semin Liver Dis 1997; 17(3): 249-260. (Pubitemid 27388062)
65. Colombato L. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension. J Clin Gastroenterol 2007; 41 (3 Suppl): S344-S351. (Pubitemid 350059461)
66. Campbell MS, Brensinger CM, Sanyal AJ, et al. Quality of life in refractory ascites: transjugular intrahepatic portal-systemic shunting versus medical therapy. Hepatology 2005; 42(3): 635-640. (Pubitemid 41233656)
67. Reisfield GM, Wilson GR. Management of intractable, cirrhotic ascites with an indwelling drainage catheter. J Palliat Med 2003; 6(5): 787-791. (Pubitemid 38435460)
68. Rosenblum Dl, Geisinger MA, Newman JS, et al. Use of subcutaneous venous access ports to treat refractory ascites. J Vasc Interv Radiol 2001 ; 12(11): 1343-1346. (Pubitemid 33069798)
69. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy -definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35(3): 716-721. (Pubitemid 34183979)
70. Das A, Dhiman RK, Saraswat VA, et al. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol 2001; 16(5): 531-535. (Pubitemid 34188860)
71. Romero-Gomez M, Boza F, Garcia-Valdecasas MS, et al. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 2001; 96: 2718-2723.
72. Romero-Gómez M, Grande L, Camacho I. Prognostic value of altered oral glutamine challenge in patients with minimal hepatic encephalopathy. Hepatology 2004; 39(4): 939-943. (Pubitemid 38428932)
73. Sundaram V, Shaikh OS. Hepatic encephalopathy: pathophysiology and emerging therapies. Med Clin North Am 2009; 93(4): 819-836.
74. Morgan MY, Alonso M, Stanger LC. Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients: a randomised, cross-over study. J Hepatol 1989; 8(2): 208-217. (Pubitemid 19074358)
75. Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy: a controlled, double-blind clinical trial. A J Dig Dis 1978; 23(5): 398-406. (Pubitemid 8347715)
76. Mas A, Rodés J, Sunyer L, et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 2003; 38(1): 51-58. (Pubitemid 36078524)
77. Laccetti M, Manes G, Uomo G, et al. Flumazenil in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double blind randomized placebo controlled study. Dig Liver Dis 2000; 32(4): 335-338. (Pubitemid 30445073)
78. Pandharipande P, Shintanl A, Peterson J, et al. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology 2006; 104(1): 21-26.
79. Nauck F, Alt-Epping B. Crises In palliative care: a comprehensive approach. Lancet Oncol 2008; 9(11): 1086-1091.
80. Monti M, Castellani L, Berlusconi A, et al. Use of red blood cell transfusions in terminally ill cancer patients admitted to a palliative care unit. J Pain Symptom Manag 1996; 12(1): 18-22. (Pubitemid 26187520)
81. Prommer E. Management of bleeding In the terminally ill patient. Hematology 2005; 10(3): 167-175. (Pubitemid 41801133)
82. El-Serag HB, Rudolph KL Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132(7): 2557-2576. (Pubitemid 46890874)
83. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334(11): 693-699. (Pubitemid 26079803)
84. Cunningham SC, Choti MA, Bellavance EC, et al. Palliation of hepatic tumors. Surg Oncol 2007; 16(4): 277-291. (Pubitemid 350193317)
85. Man-Son-Hing M, Wells G. Meta-analysis of efficacy of quinine for treatment of nocturnal leg cramps in elderly people. BMJ 1995; 310(6971): 13-17.
86. Lee FY, Lee SD, Tsai YT, et al. A randomized controlled trial of quinidine in the treatment of cirrhotic patients with muscle cramps. J Hepatol 1991; 12(2): 236-240.
87. Corbani A, Manousou P, Calvaruso V, et al. Muscle cramps in cirrhosis: the therapeutic value of quinine. Is it underused? Dig Liver Dis 2008; 40(9): 794-799.
88. Singh N, Gayowski T, Wagener MM, et al. Depression in patients with cirrhosis: impact on outcome. Dig Dis Sci 1997; 42(7): 1421-1427. (Pubitemid 27339357)
89. Kim SH, Oh EG, Lee WH. Symptom experience, psychological distress, and quality of life in Korean patients with liver cirrhosis: a cross-sectional survey. Int J Nurs Stud 2006; 43(8): 1047-1056. (Pubitemid 44511937)
90. van der Plas SM, Hansen BE, de Boer JB, et al. Generic and disease-specific health related quality of life in non-cinrhotic, cirrhotic and transplanted liver patients: a cross-sectional study. BMC Gastroenterol 2003; 3: 33.
91. Schulz R, Beach SR. Caregiving as a risk factor for mortality: the Caregiver Health Effects Study. JAMA 1999; 282(23): 2215-2219. (Pubitemid 30002964)
92. Rossaro L, Troppmann C, McVicar JP, et al. A strategy for the simultaneous provision of pre-operative palliative care for patients awaiting liver transplantation. Transpl Int 2004; 17(8): 473-475. (Pubitemid 39362578)
93. Lumby J. Liver transplantation: the death/life paradox. Int J Nurs Pract 1997; 3(4): 231-238.
94. Iredale J. End-stage chronic liver disease: time to define a good death. Hepatology 2008; 47(6): 1799-1800. (Pubitemid 351945542)